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Abstract
Background: Epidemiological studies suggest that reduced exposure to varicella might lead to an increased risk
for herpes zoster (HZ). Reduction of exposure to varicella is a consequence of varicella vaccination but also of
demographic changes. We analyzed how the combination of vaccination programs and demographic dynamics
will affect the epidemiology of varicella and HZ in Germany over the next 50 years.
Methods: We used a deterministic dynamic compartmental model to assess the impact of different varicella and
HZ vaccination strategies on varicella and HZ epidemiology in three demographic scenarios, namely the projected
population for Germany, the projected population additionally accounting for increased immigration as observed in
2015/2016, and a stationary population.
Results: Projected demographic changes alone result in an increase of annual HZ cases by 18.3% and a decrease of
varicella cases by 45.7% between 1990 and 2060. Independently of the demographic scenario, varicella vaccination
reduces the cumulative number of varicella cases until 2060 by approximately 70%, but also increases HZ cases by
10%. Unlike the currently licensed live attenuated HZ vaccine, the new subunit vaccine candidate might completely
counteract this effect. Relative vaccine effects were consistent across all demographic scenarios.
Conclusion: Demographic dynamics will be a major determinant of HZ epidemiology in the next 50 years. While
stationary population models are appropriate for assessing vaccination impact, models incorporating realistic
population structures allow a direct comparison to surveillance data and can thus provide additional input for
immunization decision-making and resource planning.
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Background
Public health consequences of demographic changes on
the incidence of non-communicable diseases have been
discussed in the context of the so-called epidemiological
transition [1–3]. However, it is usually neglected that the
epidemiology of infectious diseases, which relies on
dynamic transmission processes within populations, can
also be affected by changing population structures and
resulting changes in contact patterns. Nevertheless, in
the context of childhood infections, there are some
modelling studies available analyzing the effects of
applying realistic population models [4–7]. Due to their
increased complexity, these models usually need add-
itional calibration data as well as simplifying assumptions,
raising the question of when it may be useful to apply a
realistic population model and when these additional re-
quirements can be fulfilled.
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One example of an infectious disease affected by
demographic changes is herpes zoster (HZ), which is
caused by the reactivation of varicella zoster virus
(VZV) up to decades after initial infection, occurring
commonly during childhood as varicella. Incidence and
disease severity of HZ increase considerably with age so
that HZ disease burden is directly affected by the ageing
of a society [8]. Moreover, the risk for reactivation of
VZV seems to be reduced through contact with the
virus, e.g., by being exposed to children suffering from
varicella (boosting hypothesis) [9, 10]. Since the fre-
quency of contacts with children will decrease in an age-
ing society, overall HZ incidence is expected to increase,
especially among the elderly. Varicella vaccination will
further decrease VZV transmission and increase HZ in-
cidence due to reduced boosting opportunities [11–14].
Vaccination against HZ may potentially counteract this
effect. However, the currently licensed live attenuated
HZ vaccine is assumed to suffer from low efficacy/effect-
iveness in older age groups (the persons with the highest
complication and mortality rates), and from a short dur-
ation of protection [15, 16]. A new recombinant subunit
vaccine candidate showed a high vaccine efficacy of 91–
97% across all age groups in two recent phase III clinical
trials [17, 18].
Mathematical models developed to support decision-
making on immunization strategies rarely account for
demographic effects. The present study evaluated how
projected demographic changes in combination with vac-
cination strategies can affect the epidemiology of varicella
and HZ in Germany and to what extent demographic
changes may influence the impact of vaccination. In
addition, we assessed the robustness of the predictions in
the face of unexpected short-term demographic changes
(as currently observed due to the increased immigration
to Germany). Finally, we studied how a new HZ vaccine
candidate might affect HZ epidemiology.
Methods
Model structure
We used an extended SEIR (susceptible, exposed, infec-
tious, resistant) deterministic compartment model for
VZV described in detail elsewhere [19]. The model
(Additional file 1: Figure S1) was fitted to serological
(varicella) and incidence (HZ) data from the pre- and
post-varicella vaccination era in Germany, using age-
and sex-specific reactivation rates for HZ [19]. Details
regarding parameter values and calibration results can
be found in Additional file 1: Table S1.
Model populations
All analyses were carried out for three different popula-
tion scenarios, namely a stationary population, the
projected population for Germany, and a projected
population adjusted for the increased immigration as ob-
served in 2015/2016 in Germany (projected population
with increased migration) not anticipated by the popula-
tion projections of the Federal Statistical Office of
Germany (Destatis; https://www-genesis.destatis.de). For
the stationary population scenario, we applied age- and
sex-specific mortality rates for Germany from 2013
(using 1-year age groups) (Destatis) and a constant num-
ber of 1 million births per year (male:female ratio
1.05:1). This resulted in a stable population size of 80.6
million individuals, representing the German population
size between 1990 (79.8 million) and 2015 (80.8 million).
For the projected population, we used the age- and sex-
specific population projection (including assumed future
immigration and emigration patterns) provided by
Destatis for the years 1990 to 2060 (Fig. 1). For simpli-
city, we assumed that, in this population scenario,
migrants do not differ from the resident German popu-
lation with respect to their varicella and HZ status; this
is a reasonable assumption for individuals from other
European countries having represented the majority of
migrants in Germany before 2015. To reflect the short-
term immigration as observed in 2015/2016, we adjusted
the projected population by including an additional 1
million persons immigrating to Germany in 2015 with
an ongoing influx of migrants decreasing stepwise by
100,000 per year from 2016 to 2025 (projected popula-
tion with increased migration). As VZV seroprevalence
differs across the nine top immigration countries and is
consistently lower than in Germany, we obtained sero-
prevalence data for children and adults for each country
Fig. 1 Comparison of the age distribution of the stationary population
versus the projected populations from 1990 to 2060
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as proxy for VZV seroprevalence in immigrants
(Additional file 1: Table S2).
Contact patterns
Age-specific contact patterns were implemented based on
the POLYMOD survey (all contacts, irrespective of type
and duration of contact) [20]. Necessary changes in contact
rates over time in the projected populations caused by
varying population sizes in each age group were imple-
mented based on yearly balancing of age-specific contact
rates reported in the POLYMOD survey. For this, we used
the geometric mean of the total numbers of contacts of
each two age groups having contact with each other. In the
projected population, for example, the number of children
aged < 10 years is predicted to decrease until 2060 to 58.1%
of their number in 1990, whereas the number of persons
aged ≥ 75 years is predicted to increase to 232.7% of their
number in 1990. Consequently, the ratio between the
number of persons aged < 10 years and those aged ≥ 75
years will decrease from 1.6 in 1990 to 0.4 in 2060. The ra-
tio between the average number of contacts of children
aged < 10 years with individuals aged ≥ 75 years and vice
versa must then decrease by a factor of 1:6=0:4 ¼ 4. As we
are using the geometric mean for balancing contact rates,
the average number of contacts of children aged < 10 with
persons aged ≥ 75 will increase by
ffiffiffi
4
p ¼ 2; conversely, the
average number of contacts of persons aged ≥ 75 with chil-
dren aged < 10 will be halved (Additional file 1: Figure S4).
For the projected population with increased migration,
we assumed that, in the first year after arrival in
Germany, immigrants only have contact with other mi-
grants plus one additional contact per day to a random
person in the resident German population. Only after
this first year do some immigrants leave Germany. The
proportion of those remaining in Germany for each
country of origin was estimated with the so called
official ‘protection rates’ (proportion of accepted asylum
seekers/refugees as well as individuals granted either tem-
porary protection or deportation ban of all asylum seekers
by country). For migrants remaining in Germany, we
assumed the same contact patterns as for the resident
German population.
Modelling of vaccines and vaccination strategies
Varicella vaccine effectiveness was assumed to be 92%
(one dose) and 95% (two doses), with an average dur-
ation of vaccine-induced protection of 40 and 80 years,
respectively [19]. Vaccination coverage was set to ob-
served rates until 2010 and assumed to be constant
thereafter (86.9% for one dose at 12 months and 64.1%
for two doses at 24 months; recommended age in
Germany is 11–14 months for first dose, 15–23 months
for second dose) [19].
For the HZ vaccination scenario, one dose HZ vaccin-
ation was assumed to start in 2015 at the age of 60
years, the most effective age at HZ vaccination with re-
spect to reduction of HZ cases (Additional file 1: Figure
S6) [19]. HZ vaccination coverage was assumed to be
20% in the base case scenario and was varied from 0 to
100% in sensitivity analyses. Age-dependent vaccine effi-
cacy of the currently licensed live attenuated HZ vaccine
was based on the results of clinical trials [21–23]. We
also studied a not yet licensed recombinant subunit vac-
cine candidate that showed a very high vaccine efficacy
across all age groups in a recent phase III study in com-
bination with a longer duration of protection (estimated
as 56 years; chapter 11 in Additional file 1) [17].
Results
Effect of demographic changes on the epidemiology of
varicella and HZ (in absence of varicella and HZ
vaccination)
In the projected population, the annual number of vari-
cella cases decreased by 45.7% from 1990 until 2060
(Fig. 2, upper panel, no vaccination scenarios), while the
number of HZ cases increased by 18.3% (Fig. 3, upper
panel, no vaccination scenarios). This resulted in an
estimated number of 500,000 cases per year for each of
the two diseases in 2060. Age-specific HZ incidence
rates were only affected in individuals aged ≥ 75 years
(increase of 18.8% compared to 1990, data not shown).
As complication rates for varicella increase with age,
the overall reduction of varicella cases was counteracted
by increasing proportions of more severe varicella cases
in the growing elderly population. Therefore, the de-
crease in varicella hospitalizations from 1990 to 2060
was smaller than for cases (–42.8%), whereas the num-
ber of deaths remained almost stable (Fig. 2). For HZ,
increasing case numbers were associated with an even
greater increase in hospitalizations (from 12,585 in 1990
to 21,515 in 2060) and deaths (from 45 in 1990 to 184 in
2060; Fig. 3).
In comparison to the stationary population scenario,
the projected population scenario predicted a total of
38.3% less varicella cases and 16.4% more HZ cases (ac-
cumulated over the study period from 2004 to 2060;
Table 1). Differences in the number of hospitalizations
associated with varicella across the two population sce-
narios to some extent reflected the difference observed
for cases (–30.8%), whereas the number of deaths was
higher (+13.8%) in the projected population scenario
compared to the stationary population scenario. With
respect to HZ, there were 24.8% more hospitalizations
and 42.9% more deaths in the projected population than
in the stationary population scenario.
In the projected population with increased migration,
slightly higher numbers of varicella and HZ cases were
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predicted than in the projected population not consider-
ing increased migration. Moreover, there were slightly
more hospitalizations (varicella +9.7%; HZ +2.9%) and
HZ-associated deaths (+0.8%). The number of varicella-
associated deaths in the year 2060 increased by 46.7%,
which corresponds to a rise from 6.0 absolute cases in
the projected population to 8.8 in the projected popula-
tion with increased migration (Fig. 2).
Effects of varicella vaccination
In all three population scenarios, universal varicella vac-
cination resulted in a strong immediate decline in vari-
cella cases up to a maximum relative reduction of 90%
in 2014 when compared to corresponding scenarios
without vaccination (Fig. 2, upper panel). After 2014,
varicella case numbers increased to approximately one-
third of the cases observed in corresponding scenarios
without vaccination, mainly due to breakthrough
infections. Despite the strong overall reduction in vari-
cella case numbers, varicella case numbers increased
among persons older than 9 years due to an age-shift
(Additional file 1: Figure S5). The impact of vaccination
is opposed by the fact that complication rates increase
with age, so that the reduction in cases led to only a
small overall reduction in hospitalizations and even an
increase in deaths. However, it must be noted that, while
deaths associated with varicella increased considerably
on a relative scale, they were still very small in absolute
numbers (on average below 10 deaths per year for all of
Germany). In addition, the estimation of the total num-
ber of deaths associated with varicella (or HZ) was quite
difficult as most deaths associated with varicella occur in
multimorbid patients, where a unique definition of exact
cause of death is usually not possible.
Given the assumed reduction in boosting of immunity
against HZ, varicella vaccination increased the number
of HZ cases by a maximum of 21% in the stationary
population and 18% in both projected populations
(compared to no vaccination) in the year 2026 (Fig. 3).
In 2060, the reduced HZ incidence in varicella-
Fig. 2 Effects of varicella vaccination on varicella cases, hospitalizations, and deaths by time and population scenario (projected population 1:
predictions of the Federal Statistical Office; projected population 2: projected population with increased immigration, additionally accounting for
short-term immigration)
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vaccinated individuals already compensated for the re-
duction of boosting in all population scenarios regarding
HZ case numbers, but not for hospitalizations or deaths.
Nevertheless, in the long run, HZ cases, hospitalizations,
and deaths were reduced by more than 50% compared
to scenarios without varicella vaccination [19].
Effects of HZ vaccination
HZ vaccination with the currently licensed live attenu-
ated vaccine only had limited effects on the epidemi-
ology of HZ under base case assumptions, mainly due to
the low expected vaccination coverage of 20%, the short
duration of protection, and the age-dependent declining
efficacy. For hospitalizations and deaths associated with
HZ, the relative reduction was even smaller (Fig. 3). In
contrast, the new vaccine candidate, under the same
coverage assumptions, was able to reduce the excess HZ
cases (additional HZ cases due to varicella vaccination)
by 45–52% due to higher vaccine efficacy and longer
duration of protection (Table 2). While the currently
licensed HZ vaccine did not compensate for the 11%
excess in HZ cases (aggregated over the period 2004 to
2060) due to varicella vaccination even with 100% cover-
age, the new HZ vaccine candidate was predicted to fully
compensate for excess HZ cases at vaccination coverage
rates of approximately 40% (Additional file 1: Figures S6
and S7).
For the purpose of comparability, age of vaccination
was set for the new subunit HZ vaccine at 60 years,
which has been shown to be the best age of vaccination
regarding the reduction of overall HZ cases for the cur-
rently licensed vaccine. However, due to its longer dur-
ation of protection, a younger age at vaccination would
be even more efficient for the new subunit vaccine since
a vaccination age of 60 years would result in a lifelong
protection, even under conservative estimations for pro-
tection duration. Nevertheless, for a decision on the best
age of vaccination, more information about the loss of
Fig. 3 Effects of varicella and HZ vaccination on HZ cases, hospitalizations, and deaths by time and population scenario (projected population 1:
predictions of the Federal Statistical Office; projected population 2: projected population with increased immigration, additionally accounting for
short-term immigration)
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vaccine protection over time would be necessary. The
relative impact of both varicella and HZ vaccination
(compared to no vaccination) was similar across all
population scenarios (Table 2).
Projected future epidemiology of varicella and HZ
According to predictions from the scenario that represents
the best current population dynamics and vaccination rec-
ommendations in Germany (projected population with in-
creased migration scenario, with varicella vaccination, and
without HZ vaccination), varicella cases decreased from al-
most 1 million in 1990 to approximately 800,000 in 2003
due to demographic changes; case numbers will then fall
rapidly due to varicella vaccination and stabilize at ap-
proximately 170,000 cases from 2020 onwards (Fig. 2). HZ
cases are predicted to increase from approximately
400,000 in 1990 to 640,000 in 2033 and will then slowly
decrease to 530,000 cases in 2060. The minimum number
of varicella cases, hospitalizations, and deaths is predicted
for the year 2014 (Fig. 3). While the number of varicella
cases (–82.0%) and hospitalizations (–45.8%) will be much
smaller in 2060 than in 1990, this will not be the case for
the number of deaths (+155.9%). HZ case numbers will
peak around 2030 with the highest hospitalization and
death numbers following in 2046 and 2056. All three HZ
outcomes will be much higher in 2060 than in 1990.
Combined effects of demographic changes and
vaccination strategies
In order to assess the relative contribution of vaccin-
ation and demographic changes, we compared the
epidemiology in the years 2003 (year before varicella
vaccination) and 2060 (as predicted by the projected
population model; Table 3). The number of hospitaliza-
tions for varicella and HZ are primarily driven by demo-
graphic changes, whereas the overall case numbers for
varicella are mostly affected by vaccination strategies. In
the short run, demographic changes and varicella
vaccination lead jointly to decreasing varicella cases and
hospitalizations, and to increasing HZ cases and hospi-
talizations. In the long run, the effects of a declining
population and protection from varicella vaccination
against HZ exceed that of an aging population and ab-
sence of boosting, so that demographic changes and
varicella vaccination will also jointly lead to a decrease
regarding HZ case numbers and hospitalizations.
Discussion
We analyzed the expected changes of varicella and HZ
epidemiology due to the combined effects of demo-
graphic changes and vaccination against both varicella
and HZ. Our results show that long-term demographic
changes will be a major driver of varicella and HZ
epidemiology in the next 50 years in Germany. With de-
creasing numbers of varicella cases and increasing num-
bers of HZ cases, both diseases would have the same
incidence rates in 2060. Since not only HZ incidence,
Table 2 Relative impact of projected population scenarios on the predicted cumulative number of varicella and herpes zoster (HZ)
cases (in the period 2004–2060) by vaccination scenario
Varicella cases (differences in %a) HZ cases (differences in %a)
Projected population 1b Projected population 2c Projected population 1b Projected population 2c
No vaccination –38.31% –37.12% +16.45% +21.59%
Varicella vaccination –31.90% –28.76% +16.12% +21.35%
Varicella + HZ (current live) vaccination –31.91% –28.77% +16.05% +21.26%
Varicella + HZ (new subunit) vaccination –31.95% –28.82% +15.39% +20.60%
aCompared to the stationary population model
bWithout short-term immigration
cWith short-term immigration
Table 1 Relative impact of vaccination strategies on the
predicted cumulative number of varicella and herpes zoster (HZ)






Varicella vaccinationb –72.55% +11.15%
Varicella + HZ (current live)
vaccinationc
–72.57% +9.90%




Varicella vaccinationb –69.70% +10.84%
Varicella + HZ (current live)
vaccinationc
–69.72% +9.52%
Varicella + HZ (new subunit)
vaccinationc
–69.80% +5.18%
Projected population with increased immigration
Varicella vaccinationb –68.90% +10.94%
Varicella + HZ (current live)
vaccinationc
–68.92% +9.60%
Varicella + HZ (new subunit)
vaccinationc
–69.01% +5.29%
aCompared to scenario without varicella and HZ vaccination
bVaccination coverage 86.9%/64.1% (2004–2010 as observed)
cVaccination coverage 20%
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but also HZ hospitalization rates and case fatality rates
increase substantially with age, deaths and hospitaliza-
tions associated with HZ are predicted to increase con-
siderably. Within all three population scenarios, varicella
vaccination would lead to a massive reduction of vari-
cella cases and, when taking the boosting hypothesis into
account, to a temporary increase in HZ cases. Despite
the strong effects of demography on the epidemiology of
varicella and HZ, our study suggests that the predicted
relative impact of vaccinations was very similar across
all population scenarios.
Few previous studies have analyzed the effect of chan-
ging population structures on VZV epidemiology [5, 13].
Karhunen et al. [13] implemented structural changes in
the size and composition of the population, but did not
take into account the resulting changes in contact pat-
terns. The study by Marziano et al. [5] was, to our
knowledge, the only one which explicitly modelled
changes of contact patterns due to demographic changes
over time, but did not assess how different vaccination
strategies might interact with short- and long-term as-
sumptions on population predictions. We showed that
assumptions on population structures have a consider-
able effect on the predicted burden of disease for vari-
cella and HZ, while they have almost no effect on
vaccination impact estimates. Furthermore, migration
has little effect on the epidemiology and no effect on the
impact of vaccination.
Including complex dynamics, as performed herein by
taking demographic changes into account, comes with
the drawback that the uniqueness of the model is lost,
leading to the question of which of the simplifying as-
sumptions (e.g. stationary population vs. country-specific
population structures, stable mortality rates, or changes
in medical treatment) should and could be replaced by
realistic projections. A specific problem of using a pro-
jected population approach is the long time frame – a
period of at least 100 years is necessary to capture all
positive effects of varicella vaccination on the burden of
HZ. At the same time reasonable population projections
for the next 100 years are difficult to obtain. In particu-
lar, in Germany, Destatis provides only population pro-
jections up to the year 2060, restricting our analysis to
this period although a longer time frame would be ne-
cessary for the consideration of all positive effects of
varicella vaccination. Moreover, even supposedly certain
assumptions, such as the population projections for the
next 5 years, may at times be challenged by unpredict-
able events like the increased immigration observed in
Europe in 2015/2016.
Our study indicates that there are only small differ-
ences in model predictions when age-standardizing re-
sults, such that a potential alternative approach could be
to simply apply predictions of a stationary demographic
vaccination model to predicted changes in the popula-
tion age structure. However, this approach would not be
more efficient since most of the complexity and uncer-
tainty in the model is attributable to boosting and demo-
graphic changes; therefore, adding vaccination to the
model, which is nevertheless necessary due to the dy-
namic process, is simple and does not increase uncer-
tainty or limitations.
Strengths and limitations
The present analysis is based on the best available evi-
dence as it uses official predictions for population devel-
opment and data from the pre-vaccination era for model
calibration. Moreover, we were able to include informa-
tion on the efficacy of an HZ vaccine candidate as well
as on short-term population changes due to the migra-
tion movements in 2015/2016. The underlying model
has been tested extensively with respect to parameter
sensitivity for varicella and HZ in a stationary population
setting [19] (chapter 12 in Additional file 1).
A major limitation of our study is the uncertainty as-
sociated with the model parameters and assumptions
used in the model, in particular with regards to the
boosting hypothesis, which was the driving factor of the
effect of varicella vaccination on HZ epidemiology [19].
We used the widely accepted boosting mechanism based
Table 3 Comparison of burden of varicella and herpes zoster (HZ) for the years 2003 and 2060 in different vaccination scenarios in
the projected population model
Year 2003 2060 2060 2060 2060
Scenario Varicella vaccination no no yes yes yes
HZ vaccination no no no current live new subunit
Varicella Cases 776,007 511,908 167,422 167,241 166,659
Hospitalizations 1,752 1,192 989 987 979
Deaths 5 6 12 12 11
HZ Cases 449,896 484,723 474,080 466,465 429,361
Hospitalizations 14,453 21,515 23,540 23,305 21,215
Deaths 54 184 214 214 196
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on Brisson et al. [11] and supplemented our results with
a number of different sensitivity analyses by, for ex-
ample, considering different assumptions about the
boosting mechanism. Due to the large population size
and the high prevalence of VZV infection, the multiple
runs of a stochastic model will not differ considerably
from the deterministic model; therefore, we decided to
use a simplified deterministic modelling approach. Apart
from demographic predictions, the main uncertainty in
the model results from several unknown model parame-
ters related to VZV infection (e.g., boosting hypothesis
or waning rates of varicella or HZ vaccination) and can-
not be solved by using random stochastic fluctuations of
different realizations of the model. Since we were inter-
ested in specific effects of one of the sources of uncer-
tainty (population development) on vaccination impact,
we chose a deterministic model where all other parame-
ters were fixed. To model demographic changes we used
the geometric mean to balance changing population pro-
portions; for simplicity and due to lack of available data
we did not model changes in demographics before 1990
or potential changes over time in age-specific mixing
rates due to behavioral changes like, for example, the
establishment of day-care centres in Germany or the
population movements after the reunification of
Germany. Whereas there is plenty of information avail-
able about the epidemiology of varicella and the effects
of varicella vaccination (efficacy, effectiveness, duration
of protection), and some about the currently licensed
HZ vaccine, information on the new HZ vaccine candi-
date is based on the results of two phase III clinical trials
without information on long-term efficacy. VZV sero-
prevalence estimates were, with two exceptions, not
based on studies in migrants, but were inferred using in-
formation from their countries of origin as a proxy.
However, a first pilot study among immigrants in
Germany in 2016 provided consistent VZV seropreva-
lence estimates [24]. One major limitation of our work is
that most of the results of our study could not be vali-
dated using data from the post-vaccination era. The on-
going surveillance system for varicella and HZ cases in
Germany started in April 2005, almost 1 year after intro-
duction of varicella vaccination and is based on volun-
tary reporting, and is therefore able to measure broad
trends in disease burden; no continuous reliable record-
ing system for varicella or HZ incidence exists in
Germany. In contrast, hospitalizations and deaths associ-
ated with varicella and HZ have been recorded in
Germany in a reliable way since 2000. Nevertheless, the
absolute number of deaths is too small to recognize reli-
able trends as predicted by our model. Due to reim-
bursement issues, there is an overall trend to higher
hospitalization rates with shorter durations in Germany.
This is also true for HZ, complicating the analysis of
trends in hospitalization rates, which already started to
increase before introduction of varicella vaccination. In
most countries, just as in Germany, HZ incidence and
hospitalization rates increased considerably in the last
decades. In the US, for example, most studies suggest an
increase of HZ incidence; however, its exact extent varies
between studies. Similar to Germany, this increase oc-
curred independently of the introduction of varicella
vaccination, indicating that there must be at least one
additional factor explaining the variation. Effects of
demographic changes on HZ resulting from the boosting
hypothesis would be expected to be weaker than those
of vaccination. Therefore, even with both factors of
demographic change and varicella vaccination in place,
the observed patterns in HZ epidemiology could not be
entirely explained. In addition, this trend is not consist-
ent across studies focusing on hospitalization rates.
Conclusions
In our study, we showed that analyses based on pro-
jected population scenarios predict 11–14% more HZ
cases and 31–38% less varicella cases over the next 50
years compared to a stationary population scenario, irre-
spective of the vaccination strategy implemented. The
long-term demographic changes in Germany will have a
considerable effect on the epidemiology of both varicella
and HZ. In contrast, short-term population changes (as
observed in 2015/2016) have only minimal effects on
varicella and HZ outcomes. In addition, demographic
and vaccination effects seem to be almost independent
from each other. A stationary population approach
might therefore be sufficient if the focus of the analysis
is to assess the relative impact of vaccination strategies
compared to no vaccination. Nevertheless, assessing vac-
cination strategies in a projected population scenario will
provide a more complete picture for decision-making,
which is necessary for resource planning or a correct in-
terpretation of future surveillance data [25].
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